www.fdanews.com/articles/83356-voyager-pharmaceutical-reports-progress-in-enrollment-for-alzheimer-s-study
VOYAGER PHARMACEUTICAL REPORTS PROGRESS IN ENROLLMENT FOR ALZHEIMER'S STUDY
December 22, 2005
Voyager Pharmaceutical has announced its progress in enrolling subjects into the ALADDIN studies, Phase III double-blind, placebo-controlled trials investigating the safety and efficacy of VP4896 in the treatment of mild-to-moderate Alzheimer's disease.
A total of 64 sites are now enrolling subjects for the study. Fifty-three of the sites are located in the U.S. and Canada, with the remaining 11 in Australia. During the first two-and-a-half months of recruitment, these sites have enrolled 57 subjects.